The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework

Sintilimab combined with pemetrexed and platinum met the primary endpoint of improving progression-free survival (PFS) as a first-line therapy for nonsquamous non-small cell lung cancer (NSCLC) in the phase 3 trial ORIENT-11 (NCT03607539). As seen in similar trials, the addition of sintilimab, a PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Stephen V., Nagasaka, Misako, Stefaniak, Victoria, Gruver, Kristi, Lin, Yong, Ferry, David, Socinski, Mark A., Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226396/
https://www.ncbi.nlm.nih.gov/pubmed/35756655
http://dx.doi.org/10.3389/fonc.2022.859892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226396/
https://www.ncbi.nlm.nih.gov/pubmed/35756655
http://dx.doi.org/10.3389/fonc.2022.859892

Ejemplares similares